Gout is all about the crystals and the consequences of the disease are due to the inflammation they cause. Getting rid of urate crystals is the ultimate goal in gout, as we now know that it leads to the risk zero of flares and it normalizes the cardiovascular risk level of patients with gout.
Dr. John Cush RheumNow
2 months 2 weeks ago
FDA - a 120Year History Protecting Americans. Nice overview.
- Began 1906 (as Bureau of Chemistry) w/ Pure Food & Drugs Act
- 1930 changed to Food and Drug Administration
- 1938 Food, Drug, and Cosmetics Act
- 1960s denied thalidomide approval https://t.co/3Ey98M9sxw My https://t.co/JS36EfJ19k
Dr. John Cush RheumNow
2 months 2 weeks ago
DMARD Efficacy in RA-ILD
A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,
Dr. John Cush RheumNow
2 months 2 weeks ago
New research shows synovial lining enriched in macrophages expressing SPP1 (encoding osteopontin) in proximity to fibroblasts and fibrin deposits. SPP1+ macrophages degrade fibrin & promote fibroblast proliferation that deposit collagen & does the damage, joint remodeling. A new https://t.co/yFxwAYFPPb
Dr. John Cush RheumNow
2 months 2 weeks ago
"People wish their enemies dead—but I do not; I say give them the gout, give them the stone!" — Mary Wortley Montagu
Dr. John Cush RheumNow
2 months 2 weeks ago
Uric Acid: Is Lower Better?
There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs?
https://t.co/W5FsDC5FG0 https://t.co/7mRgkg00uV
Dr. John Cush RheumNow
2 months 2 weeks ago
Updated Algorithm for the Management of Restless Legs Syndrome
Diagnose: chronic vs intermittent RLS (no need for polysomnography)
Test Iron levels (& Rx if)
Consider: remove exacerbators; walking/massage/heat; carbidopa/ levodopa; pramipexole or ropinirole; low potency opioids; https://t.co/XdzIipw1X8
Dr. John Cush RheumNow
2 months 2 weeks ago
True or False: EULAR recommends glucocorticoids alone, without additional agents, for remission induction in life-threatening ANCA-associated vasculitis.
Did you get it right? Take this week's RheumIQ quiz at https://t.co/TBlB4pmnKa. https://t.co/4IsId6lJ4Y
Dr. John Cush RheumNow
2 months 2 weeks ago
True or False: There is an available antidote for colchicine overdose. Check your answer in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/RgJ4xEAuZA
Dr. John Cush RheumNow
2 months 2 weeks ago
The mortality gap in gout has not improved in 20 years – CV disease is the leading cause of death (2-fold increase).
For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/c12GmMaatt
Dr. John Cush RheumNow
2 months 2 weeks ago
QD Clinic: Cellulitis Paradoxes
Dr. Richard Conway, Dublin, discusses a case of cellulitis and gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026.
https://t.co/ZeYyISJrrE https://t.co/2Ih4QRa7FK
Dr. John Cush RheumNow
2 months 2 weeks ago
FDA Delays Gout Drug NASP with Complete Response Letter
On June 26, 2026, SOBI received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) that will delay a decision on NASP, pending the company's answer to questions regarding the drugs https://t.co/NmPbWmYd0p
Dr. John Cush RheumNow
2 months 2 weeks ago
Non-gout drugs that may lower uric acid – losartan, amlodipine, ACE inhibitors, fenofibrate, atorvastatin, leflunomide, vitamin C, estrogen, and high-dose ASA.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/vmNvqojAcS
Dr. John Cush RheumNow
2 months 2 weeks ago
Problems with treatment adherence in the management of gout
Compared to common medical conditions such as hypertension, type 2 diabetes, hyperlipidemia or osteoporosis, where the reported drug adherence rates are between 50% to 70%, the drug adherence for gout is 37%. This https://t.co/OoLh0HUUH2
